3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1/2
1
Status
Active not recruiting
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Sarcoma
4
Genitourinary
3
Head & Neck
2
Gynecologic
2
Gastrointestinal
2
Endocrine
2
CNS
2
Breast
2
Thoracic
1
NET
1
Lymphoid
1
Dermatologic
1
Conditions
Thyroid Cancer, Papillary
2
Sarcoma
2
Salivary Gland Neoplasms
2
Brain Neoplasms
2
Wilms Tumor
1
Sarcoma, Ewing
1
Recurrence
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neuroendocrine Tumors
1
Neuroblastoma
1
Nephroma, Mesoblastic
1
Neoplasm Metastasis
1
Melanoma
1
Medulloblastoma
1
Lymphoma, Large-Cell, Anaplastic
1
Head and Neck Neoplasms
1
Glioma
1
Colorectal Neoplasms
1
Cholangiocarcinoma
1
Central Nervous System Neoplasms
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Breast Neoplasms
1
Advanced Thyroid Cancer Patients Who Received Target Therapy
1
Interventions
Fluorodeoxyglucose F18
3
Doxorubicin
3
Cyclophosphamide
3
surufatinib
2
fludarabine
2
entrectinib
2
Radiotherapy
2
Nivolumab
2
Ifosfamide
2
Filgrastim
2
Drug Therapy
2
Cisplatin
2
tivozanib
1
tislelizumab
1
tipifarnib
1
selpercatinib
1
romidepsin
1
repotrectinib
1
regorafenib
1
pembrolizumab
1
milademetan
1
ganitumab
1
fludarabine phosphate
1
entinostat
1
dostarlimab
1
conatumumab
1
cixutumumab
1
cabozantinib
1
atezolizumab
1
alectinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Sarcoma
×
entrectinib
×
Endocrine
×
Clear all
NCT02568267
2026-05-27
STARTRK-2
Hoffmann-La Roche
Phase 2
Active not recruiting
534 enrolled
1 FDA
NCT02650401
2026-03-25
STARTRK-NG
Hoffmann-La Roche
Phase 1/2
Active not recruiting
69 enrolled
1 FDA